Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation

Europace

Volumn 17, Issue 7, 2015, Pages 1007-1017

  Camm, A John ^a   Pinto, Fausto J ^b   Hankey, Graeme J ^c,d   Andreotti, Felicita ^e   Hobbs, F D Richard ^f   Csiba, László ^g   De Freitas, Gabriel R ^g   Goto, Shinya ^g   Cantú, Carlos ^g   Gonzalez Zuelgaray, Jorge ^g   Hacke, Werner ^g   Hu, Han Hwa ^g   Mantovani, Lorenzo ^g   Yoon, Byung Woo ^g   Hu, Dayi ^g   Sim, Kui Hian ^g  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LISBON   (Portugal)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NONE

Author keywords

Atrial fibrillation; Guidelines; Oral anticoagulants; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONSENSUS DEVELOPMENT; HEALTH CARE QUALITY; HUMAN; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CARDIOLOGY; COMPLICATION; EUROPE; EVIDENCE BASED MEDICINE; ORAL DRUG ADMINISTRATION; PROTOCOL COMPLIANCE; STANDARDS; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; EUROPE; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; STROKE; TREATMENT OUTCOME; VITAMIN K;

EID: 84926611359     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv068     Document Type: Review

References (80)

1. World Health Organization. The top 10 causes of death (Fact sheet no 310). 2014. http://www.who.int/mediacentre/factsheets/fs310/en/index.html (6 January 2015, date last accessed).
2. World Heart Federation. The global burden of stroke. 2014. http://www. world-heart-federation.org/cardiovascular-health/stroke/ (6 January 2015, date last accessed).
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008;92:17-40, ix.
5. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011;13: 1110-7.
6. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De SimoneG et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
7. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 2008;52:865-8.
8. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012;142:1489-98.
9. Jørgensen HS, NakayamaH, Reith J, RaaschouHO, Olsen TS. Acute strokewith atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996;27:1765-9.
10. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
11. Brüggenjürgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Müller-Nordhorn J et al. The impact of atrial fibrillation on the cost of stroke: the Berlin Acute Stroke Study. Value Health 2007;10:137-43.
12. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart RhythmAssociation. Europace 2012;14:1385-413.
13. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry. PLoS One 2013;8:e63479.
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, HackeWet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-92.
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
17. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369: 2093-104.
18. Taillandier S, Olesen JB, ClémentyN, Lagrenade I, Babuty D, LipGYHet al. Prognosis in patients with atrial fibrillation and CHA(2)DS(2)-VASc score 0 in a communitybased cohort study. J Cardiovasc Electrophysiol 2012;23:708-13.
19. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11:315-22.
20. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-63.
21. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012;11:503-11.
22. Furie KL, Kasner SE, Adams RJ, AlbersGW, Bush RL, FaganSCet al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76.
23. You JJ, Singer DE, Howard PA, LaneDA, Eckman MH, FangMCet al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e531S-75S.
24. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
25. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-e76.
26. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
27. National Institute for Health and Care Excellence. Clinical guideline 180: the management of atrial fibrillation. 2014. http://www.nice.org.uk/guidance/CG180 (6 January 2015, date last accessed).
28. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
29. Ogawa S, Aonuma K, Tse HF, Huang D, Huang JL, Kalman J et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythmia 2014;29:190-200.
30. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban versus vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; doi: 10.1093/eurheartj/ehu367.
31. Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace 2010;12:779-84.
32. Lip GYH, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111:933-42.
33. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568-76.
34. Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167:329-34.
35. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, DaviesDWet al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
36. Breithardt G, Dobrev D, Doll N, Goette A, Hoffmann B, Kirchhof P et al. The German Competence Network on Atrial Fibrillation (AFNET). Herz 2008;33: 548-55.
37. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011;100:897-905.
38. Bosch RF, KirchW, Theuer JD, Pittrow D, Kohlhaussen A, Willich SN et al. Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int J Cardiol 2013;167:750-6.
39. Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, D'Ambrosio G, MagliaGet al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol 2013;111:705-11.
40. Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant näve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015;17:187-93.
41. Lip GY, Bongiorni MG, Dobreanu D, Lewalter T, Hastrup Svendsen J, Blomström-LundqvistCet al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace 2013;15: 1526-32.
42. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14.
43. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123:446-53.
44. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 2013;6:461-9.
45. Goto S, Ikeda Y, Chan JCN, Wilson PWF, Cheng Yeo T, Liau CS et al. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia 2011;3:93-8.
46. O'Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;168:487-94.
47. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
48. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
49. Deplanque D, LeysD, Parnetti L, Schmidt R, Ferro J, De Reuck J et al. Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge. Cerebrovasc Dis 2006;21:372-9.
50. Lugtenberg M, Burgers JS, Besters CF, Han D, Westert GP. Perceived barriers to guideline adherence: a survey among general practitioners. BMC Fam Pract 2011; 12:98.
51. Japanese Circulation Society JointWorking Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 2010;74:2479-500.
52. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 2012;76:2104-11.
53. Scottish Medicines Consortium. Rivaroxaban 15 and 20 mg film-coated tablets (Xareltow) SMC No. (756/12). 2012. http://www.scottishmedicines.org.uk/files/ advice/rivaroxaban-Xarelto-for-AF-FINAL-Jan-2012-for-website.pdf (6 January 2015, date last accessed).
54. Northamptonshire Prescribing Advisory Group. Implementation of NICE TAs 249, 256 and 275. 2013. http://www.neneccg.nhs.uk/resources/uploads/files/ implementation-of-nice-tas-249-256-and-275-dabigatran-rivaroxaban-and-apixabanapril-2013-final.pdf (6 January 2015, date last accessed).
55. NHS Dorset Clinical Commissioning Group. Position statement on oral anticoagulants in atrial fibrillation. 2014. http://www.dorsetccg.nhs.uk/Downloads/aboutus/ medicines-management/Other%20Guidelines/NOACs%20in%20AF.pdf (December 2014, date last accessed).
56. Lenti L, Brainin M, Titianova E, Morovic S, Demarin V, Kalvach P et al. Stroke care in Central Eastern Europe: current problems and call for action. Int J Stroke 2013;8: 365-71.
57. The European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
58. Agencia Española de Medicamentos y Productos Sanitarios. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales en la prevención del ictus y la embolia sistémica en pacientes con FA no valvular. Informe de utilidad terapéutica 24 de septiembre de 2012. 2012. http://www.aemps.gob.es/ medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-orales. pdf (8 January 2015, date last accessed).
59. Biskupiak J, Ghate SR, Jiao T, Brixner D. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm 2013;19: 789-98.
60. National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261. 2012. http://www.nice.org.uk/ta261 (26 January 2015, date last accessed).
61. Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics 2013;31:909-18.
62. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a costeffectiveness analysis. Clin Drug Investig 2014;34:9-17.
63. Porsdal V, Boysen G. Direct costs during the first year after intracerebral hemorrhage. Eur J Neurol 1999;6:449-54.
64. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm 2011;17:672-84.
65. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. Technology appraisal TA256. 2012. http://www.nice.org.uk/ta256 (6 January 2015, date last accessed).
66. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation.Technology appraisal TA249. 2012. http://www.nice.org.uk/ta249 (6 January 2015, date last accessed).
67. National Institute for Health and Care Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Technology appraisal TA275. 2013. http://www.nice.org.uk/guidance/TA275 (6 January 2015, date last accessed).
68. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81.
69. Lee S, AngladeMW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51.
70. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JMet al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8.
71. Freeman JV, Zhu RP, Owens DK, Garber AM, HuttonDW, Go AS et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
72. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70.
73. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105:908-19.
74. Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE et al. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic. Neurologist 2012;18:102-7.
75. Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010;8:2192-200.
76. Royal College of Physicians. Stroke improvement national audit programme (SINAP). 2012. http://www.rcplondon.ac.uk/sites/default/files/sinap-comprehensivepublic-report-2012.pdf (6 January 2015, date last accessed).
77. Canadian Stroke Network. The quality of stroke care in Canada. 2011. http://www. strokebestpractices.ca/wp-content/uploads/2011/06/QoSC-EN.pdf (6 January 2015, date last accessed).
78. Gadzhanova SV, Roughead EE, Bartlett MJ. Improving cardiovascular disease management in Australia: NPS MedicineWise. Med J Aust 2013;199:192-5.
79. Hinchey JA, Shephard T, Tonn ST, Ruthazer R, Hermann RC, Selker HP et al. The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality. J Stroke Cerebrovasc Dis 2010;19:130-7.
80. Schwamm LH, FonarowGC, Reeves MJ, PanW, Frankel MR, Smith EE et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009;119: 107-15.